Concepedia

Lisa N. Heppler

LN

Statistics

Publications

5

Citations

277

H-Index

5

Active since

2015

Affiliations

Dana-Farber Cancer Institute(Current)

Harvard University

Brigham and Women's Hospital

University of Novi Sad

Lisa N. Heppler is an author at Dana-Farber Cancer Institute specializing in pharmacology, stat3 signaling, and medicine.

Publications per year

2015–2021

5

Publications

5

Gene expression–based discovery of atovaquone as a STAT3 inhibitor and anticancer agent

Michael Xiang, Haesook Kim, Vincent T. Ho et al. · Blood · 2016 · 113 citations · Full text

, , +9

Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation

Alexandra M. Stevens, Michael Xiang, Lisa N. Heppler et al. · Blood Advances · 2019 · 59 citations · Full text

, , +14

The antimicrobial drug pyrimethamine inhibits STAT3 transcriptional activity by targeting the enzyme dihydrofolate reductase

Lisa N. Heppler, Sanaz Attarha, Rosanne Persaud et al. · Journal of Biological Chemistry · 2021 · 51 citations · Full text

, , +17

Histone Deacetylase 6 (HDAC6) Promotes the Pro-survival Activity of 14-3-3ζ via Deacetylation of Lysines within the 14-3-3ζ Binding Pocket

Jeffrey B. Mortenson, Lisa N. Heppler, Courtney J. Banks et al. · Journal of Biological Chemistry · 2015 · 39 citations · Full text

, , +16

Lipidome-based Targeting of STAT3-driven Breast Cancer Cells Using Poly- <scp>l</scp> -glutamic Acid–coated Layer-by-Layer Nanoparticles

Isidora Tošić, Lisa N. Heppler, Susana P. Egusquiaguirre et al. · Molecular Cancer Therapeutics · 2021 · 15 citations · Full text

, , +17

1–5 of 5